Boom Or Bust: Where Does PDS Biotechnology Corporation (NASDAQ: PDSB) Stock Go From Here? – Marketing Sentinel
Home  »  Technologies   »  Boom Or Bust: Where Does PDS Biotechnology Corpora...

Boom Or Bust: Where Does PDS Biotechnology Corporation (NASDAQ: PDSB) Stock Go From Here?

During the last session, PDS Biotechnology Corporation (NASDAQ:PDSB)’s traded shares were 0.55 million, with the beta value of the company hitting 2.34. At the end of the trading day, the stock’s price was $4.56, reflecting an intraday gain of 19.06% or $0.73. The 52-week high for the PDSB share is $17.85, that puts it down -291.45 from that peak though still a striking 23.9% gain since the share price plummeted to a 52-week low of $3.47. The company’s market capitalization is $135.84M, and the average intraday trading volume over the past 10 days was 0.41 million shares, and the average trade volume was 262.92K shares over the past three months.

PDS Biotechnology Corporation (PDSB) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.90. PDSB has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.23.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

PDS Biotechnology Corporation (NASDAQ:PDSB) trade information

PDS Biotechnology Corporation (PDSB) registered a 19.06% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 19.06% in intraday trading to $4.56 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -13.80%, and it has moved by -21.51% in 30 days. Based on these gigs, the overall price performance for the year is -4.20%. The short interest in PDS Biotechnology Corporation (NASDAQ:PDSB) is 0.83 million shares and it means that shorts have 1.66 day(s) to cover.

The consensus price target of analysts on Wall Street is $20.17, which implies an increase of 77.39% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15.00 and $25.00 respectively. As a result, PDSB is trading at a discount of -448.25% off the target high and -228.95% off the low.

PDS Biotechnology Corporation (PDSB) estimates and forecasts

Statistics show that PDS Biotechnology Corporation has underperformed its competitors in share price, compared to the industry in which it operates. PDS Biotechnology Corporation (PDSB) shares have gone down -56.57% during the last six months, with a year-to-date growth rate less than the industry average at -48.48% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -27.80% this quarter and then drop -50.00% in the quarter after that.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 52.30%. While earnings are projected to return 25.50% in 2022.

PDSB Dividends

PDS Biotechnology Corporation is due to release its next quarterly earnings between March 16 and March 21. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

PDS Biotechnology Corporation (NASDAQ:PDSB)’s Major holders

PDS Biotechnology Corporation insiders own 17.21% of total outstanding shares while institutional holders control 20.91%, with the float percentage being 25.26%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 79 institutions own stock in it. As of Dec 30, 2021, the company held over 1.01 million shares (or 3.57% of all shares), a total value of $8.22 million in shares.

The next largest institutional holding, with 0.53 million shares, is of Two Sigma Advisers, LP’s that is approximately 1.85% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $4.27 million.

Also, the Mutual Funds coming in first place with the largest holdings of PDS Biotechnology Corporation (PDSB) shares are Vanguard Total Stock Market Index Fund and Invesco ETF Tr II-Invesco DWA Small Cap Momentum ETF. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.65 million shares. This amounts to just over 2.27 percent of the company’s overall shares, with a $5.24 million market value. The same data shows that the other fund manager holds slightly less at 0.39 million, or about 1.38% of the stock, which is worth about $3.87 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts